Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as equipment repair services.
Read More…
Industry, Sector and Symbol
Industry Medical & hospital equipment
Sub-IndustryHealth Care Distributors
SectorMedical
Phone631-843-5500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$13.20 billion
Profitability
Miscellaneous
Employees18,000
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Henry Schein (NASDAQ:HSIC) Frequently Asked Questions
What is Henry Schein's stock symbol?
Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."
When did Henry Schein's stock split? How did Henry Schein's stock split work?
Shares of Henry Schein split on the morning of Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly minted shares were distributed to shareholders after the closing bell on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.
How will Henry Schein's stock buyback program work?
Henry Schein announced that its Board of Directors has authorized a stock repurchase plan on Thursday, December 13th 2018, which permits the company to buyback $400,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 3.1% of its stock through open market purchases. Stock buyback plans are often a sign that the company's management believes its stock is undervalued.
How were Henry Schein's earnings last quarter?
Henry Schein, Inc. (NASDAQ:HSIC) issued its earnings results on Tuesday, August, 6th. The company reported $0.84 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.83 by $0.01. The company had revenue of $2.45 billion for the quarter, compared to analysts' expectations of $2.48 billion. Henry Schein had a return on equity of 16.67% and a net margin of 4.18%. The business's revenue for the quarter was up 5.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.04 earnings per share. View Henry Schein's Earnings History.
When is Henry Schein's next earnings date?
What guidance has Henry Schein issued on next quarter's earnings?
Henry Schein updated its FY19 earnings guidance on Tuesday, August, 6th. The company provided earnings per share guidance of $3.38-3.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.45.
What price target have analysts set for HSIC?
17 Wall Street analysts have issued 1-year target prices for Henry Schein's shares. Their predictions range from $62.00 to $96.00. On average, they expect Henry Schein's share price to reach $73.4608 in the next twelve months. This suggests a possible upside of 18.3% from the stock's current price. View Analyst Price Targets for Henry Schein.
What is the consensus analysts' recommendation for Henry Schein?
17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last year. There are currently 5 sell ratings, 8 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Henry Schein.
Has Henry Schein been receiving favorable news coverage?
Media stories about HSIC stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Henry Schein earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Henry Schein.
Who are some of Henry Schein's key competitors?
Some companies that are related to Henry Schein include Siemens Healthineers (SHL), Commonwealth Bank of Australia (CSLLY), Regeneron Pharmaceuticals (REGN), ESSILOR INTL S/S (ESLOY), RESMED/IDR UNRESTR (RMD), Zimmer Biomet (ZBH), Takeda Pharmaceutical (TKPYY), McKesson (MCK), ASTELLAS PHARMA/ADR (ALPMY), COLOPLAST A/S/ADR (CLPBY), Takeda Pharmaceutical (TAK), LONZA GRP AG/ADR (LZAGY), FRESENIUS SE &/S (FSNUY), Alexion Pharmaceuticals (ALXN) and TERUMO CORP/ADR (TRUMY).
What other stocks do shareholders of Henry Schein own?
Who are Henry Schein's key executives?
Henry Schein's management team includes the folowing people:
- Mr. Stanley M. Bergman, Exec. Chairman & CEO (Age 69)
- Mr. James P. Breslawski, Vice Chairman & Pres (Age 65)
- Mr. Steven Paladino, Exec. VP, CFO & Exec. Director (Age 62)
- Mr. Gerald A. Benjamin, Exec. VP, Chief Admin. Officer & Director (Age 66)
- Mr. Mark E. Mlotek, Exec. VP, Chief Strategic Officer & Director (Age 63)
Who are Henry Schein's major shareholders?
Henry Schein's stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (11.38%), Longview Partners Guernsey LTD (10.47%), BlackRock Inc. (7.31%), Generation Investment Management LLP (7.02%), Atlanta Capital Management Co. L L C (4.28%) and Mackenzie Financial Corp (2.56%). Company insiders that own Henry Schein stock include Barry J Alperin, David Mckinley, E Dianne Rekow, Gerald A Benjamin, James P Breslawski, Mark E Mlotek, Michael S Ettinger, Paul Brons, Paul Rose, Philip A Laskawy, Stanley M Bergman, Steven Paladino and Walter Siegel. View Institutional Ownership Trends for Henry Schein.
Which institutional investors are selling Henry Schein stock?
HSIC stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Generation Investment Management LLP, BlackRock Inc., Mackenzie Financial Corp, Janus Henderson Group PLC, Janus Henderson Group PLC, Price T Rowe Associates Inc. MD and Swedbank. Company insiders that have sold Henry Schein company stock in the last year include David Mckinley, E Dianne Rekow, Gerald A Benjamin, James P Breslawski, Michael S Ettinger, Paul Brons, Philip A Laskawy, Stanley M Bergman, Steven Paladino and Walter Siegel. View Insider Buying and Selling for Henry Schein.
Which institutional investors are buying Henry Schein stock?
HSIC stock was purchased by a variety of institutional investors in the last quarter, including Longview Partners Guernsey LTD, APG Asset Management N.V., AQR Capital Management LLC, Nuveen Asset Management LLC, Wells Fargo & Company MN, Vanguard Group Inc., Renaissance Technologies LLC and Allianz Asset Management GmbH. View Insider Buying and Selling for Henry Schein.
How do I buy shares of Henry Schein?
Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Henry Schein's stock price today?
One share of HSIC stock can currently be purchased for approximately $62.12.
How big of a company is Henry Schein?
Henry Schein has a market capitalization of $9.21 billion and generates $13.20 billion in revenue each year. The company earns $535.88 million in net income (profit) each year or $4.13 on an earnings per share basis. Henry Schein employs 18,000 workers across the globe.View Additional Information About Henry Schein.
What is Henry Schein's official website?
How can I contact Henry Schein?
Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at 631-843-5500 or via email at [email protected]
MarketBeat Community Rating for Henry Schein (NASDAQ HSIC)
MarketBeat's community ratings are surveys of what our community members think about Henry Schein and other stocks. Vote "Outperform" if you believe HSIC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSIC will underperform the S&P 500 over the long term. You may vote once every thirty days.
